Elixiron Immunotherapeutics
Company Details
Status: Private
Employees: 11-50
Location:
Taipei, Taiwan
Type:
sample
Technology:
sample
sample
sample
About: Elixiron Immunotherapeutics is driven by a multi-cultural, international team in Shanghai, Taipei, the USA (San Francisco) and Switzerland (Lausanne) with a shared vision to build a global company that brings next-generation immunotherapies to patients in need. This vision drives our mission to target rare and immunological diseases as well as cancer for indications that could substantially benefit from advances in immunotherapy approaches. We employ advances in translational medicine to identify targets from clinical observations, and various drug modalities including biologics derived from a proprietary human antibody domain phage display library and a single human B cell antibody cloning platform to develop innovative therapies. Our two lead pipeline candidates are in phase 1 clinical trials. EI-1071, a small molecule inhibitor of CSF-1R kinase activity, is being explored as a potential therapy for Alzheimer's disease as well as tenosynovial giant cell tumors, and a monoclonal antibody, EI-001 is being developed for the treatment of vitiligo and other immunological disorders.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Elixiron Immunotherapeutics | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.